cyrilzakka/clinical-trials huggingface dataset:
Eating Habits of Adults During the Quarantine

The aim of this study is to assess the changes in the dietary habits of adults spending most of their time in their homes due to the Coronavirus (COVID-19) outbreak. Eating habits of individuals may vary greatly depending on several factors such as geographic location, socioeconomic conditions, education level, knowledge about nutrition and psychological factors. Since this period of quarantine is economically and psychologically stressful, we hypothesise that individuals may alter their usual eating habits.

Since the World Health Organisation (WHO) declared the latest Coronavirus outbreak as a 'pandemic', most countries had to take strict measures such as travel bans and lock-downs to prevent the spread of the virus. Unfortunately, this unexpected situation has caused many people around to globe to panic buy and stock up on food for an unpredictable period of time as it cannot be estimated when the outbreak will be controlled.

Nutrition plays an important role in our everyday life; it makes up a large part of a healthy life, it brings individuals together to socialise around a table and sometimes it can be used in times of stress as a coping mechanism leading to emotional eating.

In this study it is hypothesised that adults may tempt to change their everyday eating habits due to social isolation. Humans are generally sociable beings and this period of social isolation will psychologically pressurise humans and may cause some of them to eat more in quantity or frequency as a mechanism to cope with the growing fear and anxiety. On the other hand, it is also hypothesised that, some individuals may prefer healthier ways of eating, such as consuming more fruits and vegetables, drinking more water etc, believing that if they can improve their immunity they will be less likely to contract the virus. The study may also show that some individuals will be highly impacted economically and this will alter their dietary preferences.

Within the scope of this study an online survey consisting of 20 questions will be asked to volunteers who are over the age of 18 and spend most of their time at home in social isolation because of the Coronavirus outbreak. The survey does not include any personal questions but only general demographic data including gender, age range, the country they are currently residing, quarantine duration and whether or not they have observed any changes in their eating patterns since the beginning of this period.

In some questions, observed changes, if any, are further investigated to include details such as increase/decrease in portion size, frequency of meals etc.

Eligibility Criteria:
Inclusion Criteria:

* Being between the ages of 18-80
* Spending most of their time at home in quarantine because of the Coronavirus outbreak not to contract the virus
* Having internet access
* Being able to read and comprehend English language

Exclusion Criteria:

* Having any mental impairment or degeneration
* Having any life-threatening health condition
Molecular Diagnosis of Syndromic or Isolated Severe Intellectual Disability Using Whole Exome Sequencing : a Pilot Study

Evaluation of diagnostic whole exome sequencing in patients with syndromic or isolated severe intellectual disability without a molecular diagnostic, with suspected autosomal recessive inheritance, allowing accurate genetic counseling in this high risk of recurrence group of diseases


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of syndromic or isolated severe intellectual disability (IQ \<50) without a molecular diagnosis
* Recurrence in siblings (multiplex families) suggesting autosomal recessive inheritance (with or without parental consanguinity) or sporadic cases from a consanguineous union
* Conventional genetic tests performed (including array-CGH) and MRI/CT-scan available
* DNA samples from parents and from both unaffected or affected siblings available, for parental segregation and confirmation of candidate variations identified.
* Availability of a signed informed consent
* To be affiliated or beneficiary of French social security/healthcare system

Exclusion Criteria:

* Parents in the exclusion period of another study or as provided by the national register of volunteers
* High-probability diagnostic hypothesis for which a molecular test is available at lower cost than exome sequencing
Comparative Effects of Exergaming Versus Task Oriented Training Among Sub-acute Post-stroke Patients

This study is a randomized control trail and the purpose of this study is to determine the effects of exergaming versus task oriented training among sub-acute post-stroke patients.

Effects of exergaming training will be assessed for trunk control which includes the parameters of balance and posture.

Sub-acute post stroke patients aged 40-85 years The participants will be assessed through Trunk impairment scale (TIS), Berg Blanace Scale (BBS) and biodex (clinical test for sensory integration in balance).

Informed consent will be taken after which the participants will be recruited into the two groups, where one group will receive intervention through exergaming and other group will receive task oriented trainig.

Baseline and post-treatment measurements will be taken for analysis.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with sub-acute post-stroke.
* Aged 40 years-85 years.
* Mini-mental status examination \>24
* Motor assessment scale (1-5 scoring)

Exclusion Criteria:

* Post-stroke patients with major cognitive deficits.
* Acute infections.
* Patients with any fracture/ MSK disorders.
* Neurological deficits other than stroke
Effects of Mother-infant Skin-to-skin Contact in Postpartum Women

When a newborn is delivered in good physiological condition, immediate skin-to-skin contact with the mother is required. Skin-to-skin contact has a wide range of benefits for both mother and baby. The implementation time can start from the birth of the newborn and continue until thereafter. There are benefits both in the short and long term, such as physiological stability, parent-child relationship development, and stability of children's behavioral development. There were 108 cases admitted and the attrition rate was 10%. Therefore, the total number of cases admitted was 118, divided into experimental groups and control groups, and intervention measures were implemented in the experimental group. From the 1st to the 30th day after delivery, there is 1 hour of skin-to-skin contact between mother and baby every day. Fill out the Sleep Quality Visual Analog Scale, Maternal Confidence Scale, and Mother-Infant Bonding Scale on the day after delivery and at one month later.

According to the World Health Organization's clinical care guidelines for childbirth, neonatal care in the third stage of labor: When the newborn is delivered in good physiological condition, it needs to have skin-to-skin contact with the mother immediately. Skin-to-skin contact has extensive benefits for both mother and baby. The implementation time can start from the birth of the newborn and continue thereafter. It has benefits in both the short and long term, such as physiological stability, parent-child relationship development, and child behavioral development stability, etc. Therefore, this study was designed as a quasi-experimental study, using a random method to accept cases. The number of admitted cases was 128, and the attrition rate was 10%. Therefore, the total number of admitted cases was 140, divided into experimental groups and control groups, with intervention measures for the experimental group, and intervention measures. From the 1st to 30th day after delivery, there was 1 hour of skin-to-skin contact between mother and baby every day. On the postpartum day and at the full moon, the sleep quality visual analog scale, maternal confidence scale, and mother-infant bonding scale were filled in, and the statistical method was chi-square. Test, independent sample t test, sample t test, Pearson correlation test, simple regression analysis of the relationship between independent variables and dependent variables and the difference between the experimental group and the control group.

Eligibility Criteria:
Inclusion Criteria:

1. Vaginal delivery to primiparous women
2. Full-term delivery over 37 weeks
3. The pregnancy and delivery process are low-risk cases
4. Can listen, listen, read and write Chinese
5. Agree to participate in this study
6. No mental condition
7. The newborn's vital signs are stable after birth
8. The body appearance is normal after birth and there are no other complications.
9. Can be discharged from hospital together with mother

Exclusion Criteria:

(1)Transfer of newborn to sick nursery after birth
The ECMOCYP (cytochromes P450 Activity) Study

Prospective open label observational study including patients requiring a tMCS (VA-ECMO or Impella® CP) or in in cardiogenic shock according to the SCAI (Society for Cardiovascular Angiography and Interventions) ESC (European Society of Cardiology) definition 41,42 and not requiring or not eligible to tMCS (ECMO, Impella®, intra-aortic balloon pump) (control group).

The Geneva cocktail will be administered on 2 occasions at D3 after tMCS implantation (or start of the cardiogenic shock) and 14 days after tMCS explantation (or cardiogenic shock termination defined as: no need to use inortropic or vasopressive agent and absence of organ insufficiency)

Primary endpoint:

* Evaluate the impact of tMCS on the activity of CYPs as measured with metabolic ratios MRs (CYP activity at
* D3 post tMCS implantation and 14 days after tMCS explantation vs the activity of CYPs in the control group.

Secondary endpoints:

* Evaluate the correlation between the activity of CYPs and IL-6 levels
* Evaluate the correlation between the activity of CYPs and CRP levels
* Evaluate the correlation between the activity of CYPs and TNF-α levels
* Evaluate the correlation between the activity of CYPs and IL-1β levels
* Evaluate the correlation between the activity of CYPs and IFN-γ levels
* Compare CYP activity vs expected CYP activity based on patients' CYP genotyping
* Compare CYP activity between VA-EMCO and micro-axial pump device (Impella® CP)

Eligibility Criteria:
Inclusion Criteria:

* Male and female patients presenting a refractory cardiogenic shock, requiring temporary mechanical circulatory support (tMCS), with either the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or a micro-axial pump device (Impella® CP).
* Male and female patients in cardiogenic shock according to the SCAI (Society for Cardiovascular Angiography and Interventions) ESC (European Society of Cardiology) definition and not requiring or not eligible to temporary mechanical circulatory support (tMCS). (e.g. ECMO, Impella®, intra-aortic balloon pump) (control group)
* Age \> 18 years old
* Comprehension of French
* Ability to give consent (consent will be sought from the therapeutic representative or from relatives as the patient will be sedated and intubated. Definitive consent will be sought at patient's second blood sample planned after tMCS explantation (in case of patient's favorable outcome).

Exclusion Criteria:

* Male and female patients presenting a refractory ARDS requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO)
* Inability to receive the Geneva cocktail by enteral way
* Severe or terminal Renal impairment (defined as GFR\<30ml/min according to Cockroft-Gault)
* Severe chronic hepatic insufficiency (CHILD B-C)
* Sensitivity to any of the drugs used in the Geneva Cocktail
* Intake of drugs altering CYPs activity (Strong inhibitor or inducer based on https://www.hug.ch/sites/hde/files/structures/pharmacologie_et_toxicologie_cliniques/a5_cytochromes_6_2.pdf)
Confocal Laser Endomicroscopy in IBS Patients

This study will assess dynamic effects of two major antigens on the duodenal mucosa by confocal laser endomicroscopy (CLE). Patients will be blinded to the antigens used (wheat, yeast). Following CLE it is planned to have a cross over exclusion diet with/without the antigens including a washout phase. Furthermore, patients will undergo a 2 week FODMAP diet to be able to compare results found of both diets and allow to understand whether our findings of food intolerance will be better and more precise than a common FODMAP diet.

Post CLE food challenge patients biopsies will be taken for histology. They will then be randomized into two groups and blinded to the diet they undergo. They will be provided with a supply of custom-made bread they will have for 2 weeks (custom made by a bakery in Kiel). For one study arm bread will contain either wheat and yeast, for the other arm the bread will not contain these ingredients. The taste of the "normal" bread will be denaturised. Crossover will take place after a two-week washout phase.


Eligibility Criteria:
Inclusion Criteria:

IBS according to the Rome III criteria moderate/severe refractory daily symptoms \>1year (FGID-C1) sub classified as IBS-D, constipation predominant (IBS-C) or mixed type (IBS-M) no past infection to trigger symptom no structural/ biochemical cause of their symptoms identified negative gastroscopy, colonoscopy including histology Worsening symptoms after meals various exclusion diets - ineffective females not menstruating during CLE no known allergy to methylene blue or fluorescein Age \>18 years Negative routine testing for food intolerance (or known lactose/fructose intolerance) Positive informed consent

Exclusion Criteria:

no consent known reason for the abdominal pain and bloating other than lactose/fructose intolerance M. Whipple Known infectious gastrointestinal disease Stricture in the upper gastrointestinal tract Age \<18years Impaired renal function (Creatinine \>1.2 mg/dL) Pregnancy or breast-feeding Inability to obtain informed consent Active GI Bleeding Known allergy to Methylene blue or Fluorescein Participation in other clinical trials within the last 4 weeks
Comparison of Three Methods of Hemoglobin Monitoring

This study will further investigate the Masimo SpHb \[FDA Approved\] continuous non-invasive hemoglobin monitor in spine surgery patients. (See NCT00792597) We will investigate the effect of enhanced circulation to the finger (which will be attached to the sensor) following a local injection (digital block) of lidocaine (an FDA approved local anesthetic), and assess the accuracy of the SpHb reading as it relates to a standard laboratory hemoglobin value (tHb).

We have completed a study with 20 patients using the latest version of the SpHb monitor software and finger sensor.

The purpose of this study is to assess the accuracy of the SpHb reading as it relates to a standard laboratory hemoglobin value (tHb) following the digital block.

Eligibility Criteria:
Inclusion Criteria:

* Male or non-pregnant female 18 y/o or older
* ASA Classification 1, 2 or 3
* Scheduled to undergo spine or hip revision surgery

Exclusion Criteria:

* Pregnant or nursing
* Patients who in the study investigators clinical judgement would not be suitable for research.
DCB for Dialysis Access Stent Graft Restenosis

Recurrent stenosis in hemodialysis access graft (AVG) is difficult to treat. For recurrent stenosis in the anastomotic junction can be treated by stent graft to improve long-term patency. However, there is no data regarding treatment of stent graft restenosis in AVG. This randomized trial is designed to compare the efficacy and safety of drug-coated balloon (DCB) versus regular balloon in AVG stent graft restenosis.

Prosthetic arteriovenous hemodialysis access graft (AVG) has high incidences of venous anastomotic stenosis and access failure. A stent graft can be used in AVG with recurrent venous anastomotic stenosis to improve long-term patency rate. However, after stent graft implementation, the effective treatment for restenosis in a stent graft is still unknown. This randomized trial is designed to evaluate the efficacy and safety of drug-coated balloon versus regular balloon for in-stent restenosis in stent graft. The investigators plan to enroll 40 patients who presented with prosthetic AVG in-stent restenosis, and then to evaluate the restenosis lesions by intravascular ultrasound. Patients will be randomized into two groups of treatment: drug-coated balloon angioplasty or regular balloon angioplasty.

Eligibility Criteria:
Inclusion Criteria:

* Age of 20 to 90 years on regular hemodialysis at least 3 months
* Had stent graft implemented at dialysis vascular access
* Angiographic evidence of stenosis within the stent graft or less than 2 cm from the stent graft edge
* Clinical evidence of a hemodynamically significant stenosis or thrombosis
* Patient is able to provide written informed consent

Exclusion Criteria:

* Elbow fracture or any disease involve the elbow joint that prohibits the flexion maneuver.
* Target lesion cannot be crossed by the guide wire.
* Known hypersensitivity to heparin or contrast medium.
* Bleeding diathesis.
* Patients participating in another clinical trial with interfering with this trial in the past three months.
* Untreatable bleeding diathesis.
* Other diseases, such as cancer, liver disease, or cardiac insufficiency, which may lead to protocol violations or markedly shorten a patient's life expectancy (less than 3 months).
* Patients unable or unwilling to participate this trial.
* Pregnancy, lactating woman, non-adult, criminals in sentence, psychiatric patients, research staffs or colleagues are prohibited.
Interplay Between Adherence to the Mediterranean Diet, Lipid Profile and Blood Pressure: a Comparative Survey Among Healthcare and Non-Healthcare Female Workers

The study aims at testing the level of adherence to the Mediterranean diet among health-workers, comparing this aspect to the extra-working physical activity, anthropometric measures and prevalence of cardiovascular, metabolic and neoplastic diseases previously diagnosed.

The study had a cross-sectional setting and included employees of both genders currently in service.

Baseline data collection was structured as follows:

* Clinical assessment and pathological history
* Anthropometric measurements;
* Haematochemical examinations;
* Screening to adherence to Med-Diet by using "MedDietScore" questionnaire
* Assessment of the Harvard Cancer Risk Index for the evaluation of risk factors, modifiable and not, of the most frequent oncological diseases in Italy (colon, lung, breast and prostate). The index provides an estimate of individual cancer risk and is not equivalent to a cancer diagnosis. In addition, the Harvard Cancer Risk Index itself can allow the doctor to advise the worker on useful measures to reduce it;
* International Physical Activity Questionnairre (IPAQ)
* Major anthropometric and haematochemical data also allow to obtain one of the most used risk indexes for cardiovascular diseases in the scientific literature the Framingham Score.

Eligibility Criteria:
Inclusion Criteria:

* Women of working age
* Level of education at least equal to Bachelor's degree

Exclusion Criteria:

* Men
* Women under 20 years old or over 65 years old
A Trial of HR18034 in Inguinal Hernia Repair

Phase I, randomized, double-blind, comparator-controlled study to assess the safety, PK, and efficacy of single postsurgical application of HR18034 compared with Naropin®


Eligibility Criteria:
Inclusion Criteria:

Able and willing to provide a written informed consent 2、Male or female between 18 and 70 years of age 3、Scheduled to undergo a primary, inguinal hernia repair with mesh, and be able to use the anesthesia regimen 4、Meet the body mass 5、Conform to the ASA Physical Status Classification

Exclusion Criteria:

1. Clinically significant abnormal clinical laboratory test value
2. Subjects with poor blood pressure control after medication
3. Subjects with atrioventricular block or cardiac insufficiency
4. Subjects with a history of myocardial infarction or unstable angina pectoris
5. Subjects with a history of ischemic stroke or transient ischemic attack
6. Combination of other pain conditions that may affect postoperative pain assessment
7. Allergic to a drug ingredient or component
8. Persistent or recurrent nausea and/or vomiting due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer
9. History of alcohol abuse or prescription and/or illicit drug abuse within 1 years
10. Subjects with special diets (including tobacco, grapefruit and caffeine)
11. Positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol abuse.
12. History of human immunodeficiency virus (HIV), hepatitis C, syphilis antibody，or hepatitis B.
13. Use of any of the following medications within 14 days or as specified prior to the study surgical procedure:
14. Have had an inguinal hernia repair in the last 3 months before the study surgical procedure or presents with bilateral or recurrent inguinal hernia, other hernia presentations, or hernias with a large scrotal component that would be difficult to reduce surgically
15. Participated in clinical trials of other drugs (received experimental drugs)
16. History or clinical manifestations of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other condition.
17. Pregnant or nursing women
18. No birth control during the specified period of time
19. The inestigators determined that other conditions were inappropriate for participation in this clinical trial
Bioavailability of Flucanazole

The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Flucanazole 40mgm/ml 35 ml Suspension and Pfizer (Diflucan®) 40 mg/ml 35 ml Fluconazole Suspension Under Fed Condition

The study is to be conducted as an open-label, randomized, single-dose, 2-way crossover, relative bio availability study performed on 200 healthy adult volunteers. A total 200 subjects will be assessed for AUC for 72 hours after administration of flucanazole suspension

Eligibility Criteria:
Inclusion Criteria Male and females between the ages of 18 and 35 years

* Healthy Individual
* Able to swallow

Exclusion Criteria:

* History or presence of significant:

  * cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease.

In addition, history or presence of:

alcoholism or drug abuse within the past year; hypersensitivity or idiosyncratic reaction to fluconazole or other azoles. Subjects who have used any drugs or other substances known to be strong inhibitors of CYP (cytochrome P450) enzymes within 10 days prior to first dose.

Subjects who have used any drugs or other substances known to be strong inducers of CYP (cytochrome P450) enzymes within 30 days prior to first dose.

Subjects who have been anormal diet during the 30 days prior to the first dosing.